$CATX
Perspective Therapeutics Inc Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000143774921026208 Filed on November 10, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$2.816M	$2.564M	$2.384M
YoY Change	19.37%	7.55%	2.98%
Cost Of Revenue	$1.596M	$1.535M	$1.138M
YoY Change	33.89%	34.89%	5.47%
Gross Profit	$1.220M	$1.029M	$1.246M
YoY Change	4.54%	-17.42%	0.81%
Gross Profit Margin	43.32%	40.13%	52.27%
Selling, General & Admin	$2.320M	$2.601M	$1.648M
YoY Change	32.72%	57.83%	-13.81%
% of Gross Profit	190.16%	252.77%	132.26%
Research & Development	$535.0K	$702.0K	$312.0K
YoY Change	87.72%	125.0%	33.91%
% of Gross Profit	43.85%	68.22%	25.04%
Depreciation & Amortization	$71.00K	$59.00K	$34.00K
YoY Change	54.35%	73.53%	-10.53%
% of Gross Profit	5.82%	5.73%	2.73%
Operating Expenses	$2.855M	$3.303M	$1.960M
YoY Change	39.95%	68.52%	-5.41%
Operating Profit	-$1.635M	-$2.274M	-$714.0K
YoY Change	87.29%	218.49%	-14.59%
Interest Expense	$31.00K	$31.00K	$1.000K
YoY Change	520.0%	3000.0%	-95.0%
% of Operating Profit
Other Income/Expense, Net	$31.00K	$31.00K	$1.000K
YoY Change	520.0%	3000.0%	-95.0%
Pretax Income	-$1.604M	-$2.243M	-$713.0K
YoY Change	84.79%	214.59%	-12.62%
Income Tax
% Of Pretax Income
Net Earnings	-$1.604M	-$2.243M	-$713.0K
YoY Change	84.79%	214.59%	-12.62%
Net Earnings / Revenue	-56.96%	-87.48%	-29.91%
Basic Earnings Per Share	-$0.01	-$0.02	-$0.01
Diluted Earnings Per Share	-$11.30K	-$15.81K	-$10.35K
COMMON SHARES
Basic Shares Outstanding	141.9M	141.9M	68.90M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.35M	$61.69M	$1.940M
YoY Change	529.67%	3079.9%	-57.6%
Cash & Equivalents	$60.35M	$61.69M	$1.940M
Short-Term Investments
Other Short-Term Assets	$535.0K	$306.0K	$407.0K
YoY Change	77.74%	-24.82%	94.74%
Inventory	$1.068M	$1.060M	$641.0K
Prepaid Expenses
Receivables	$1.647M	$1.902M	$1.758M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$63.60M	$64.96M	$4.746M
YoY Change	417.57%	1268.69%	-30.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.973M	$1.953M	$1.814M
YoY Change	7.81%	7.66%	8.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$110.0K	$120.0K	$128.0K
YoY Change	-7.56%	-6.25%	-15.23%
Total Long-Term Assets	$3.648M	$3.752M	$3.279M
YoY Change	13.15%	14.43%	-1.18%
TOTAL ASSETS
Total Short-Term Assets	$63.60M	$64.96M	$4.746M
Total Long-Term Assets	$3.648M	$3.752M	$3.279M
Total Assets	$67.25M	$68.71M	$8.025M
YoY Change	333.52%	756.2%	-20.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$847.0K	$768.0K	$758.0K
YoY Change	69.4%	1.32%	-22.97%
Accrued Expenses	$998.0K	$1.031M	$764.0K
YoY Change	18.67%	34.95%	12.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.845M	$1.799M	$1.522M
YoY Change	38.2%	18.2%	-8.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.016M	$1.152M	$1.408M
YoY Change	-27.69%	-18.18%	-6.32%
Total Long-Term Liabilities	$1.016M	$1.152M	$1.408M
YoY Change	-27.69%	-18.18%	-6.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.845M	$1.799M	$1.522M
Total Long-Term Liabilities	$1.016M	$1.152M	$1.408M
Total Liabilities	$2.861M	$2.951M	$2.930M
YoY Change	4.42%	0.72%	-7.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$95.17M	-$93.57M	-$88.65M
YoY Change	6.31%	5.55%	3.92%
Common Stock	$159.6M	$159.3M	$93.75M
YoY Change	55.99%	69.96%	1.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$64.39M	$65.76M	$5.095M
YoY Change
Total Liabilities & Shareholders Equity	$67.25M	$68.71M	$8.025M
YoY Change	333.52%	756.2%	-20.73%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$1.604M	-$2.243M	-$713.0K
YoY Change	84.79%	214.59%	-12.62%
Depreciation, Depletion And Amortization	$71.00K	$59.00K	$34.00K
YoY Change	54.35%	73.53%	-10.53%
Cash From Operating Activities	-$1.313M	-$2.084M	-$338.0K
YoY Change	72.76%	516.57%	-48.24%
INVESTING ACTIVITIES
Capital Expenditures	-$81.00K	$54.00K	$113.0K
YoY Change	35.0%	-52.21%	15.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$81.00K	-$54.00K	-$113.0K
YoY Change	35.0%	-52.21%	15.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	56.00K	$0.00
YoY Change	-99.34%
NET CHANGE
Cash From Operating Activities	-1.313M	-$2.084M	-$338.0K
Cash From Investing Activities	-81.00K	-$54.00K	-$113.0K
Cash From Financing Activities	56.00K	$0.00
Net Change In Cash	-1.338M	-$2.138M	-$451.0K
YoY Change	-117.5%	374.06%	-39.95%
FREE CASH FLOW
Cash From Operating Activities	-$1.313M	-$2.084M	-$338.0K
Capital Expenditures	-$81.00K	$54.00K	$113.0K
Free Cash Flow	-$1.232M	-$2.138M	-$451.0K
YoY Change	76.0%	374.06%	-39.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	141915266
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	63000	USD
CY2021Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-175000	USD
CY2020Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-18000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141915266
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141915266
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141915266
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141915266
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M21D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.72
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.68
CY2020Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61690000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63828000	USD
CY2021Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	1902000	USD
CY2021Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2013000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	1060000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	980000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	306000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	481000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	64958000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	67302000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1953000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1958000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	705000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	768000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	USD
CY2021Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	792000	USD
CY2021Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	76000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	120000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2021Q3	us-gaap	Assets Assets	68710000	USD
CY2021Q2	us-gaap	Assets Assets	70416000	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	768000	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	730000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	252000	USD
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	120000	USD
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	98000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	102000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	100000	USD
CY2021Q3	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	300000	USD
CY2021Q2	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	362000	USD
CY2021Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	253000	USD
CY2021Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	259000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1799000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1801000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	459000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	524000	USD
CY2021Q3	isr	Accrued Payroll And Related Taxes Noncurrent AccruedPayrollAndRelatedTaxesNoncurrent	77000	USD
CY2021Q2	isr	Accrued Payroll And Related Taxes Noncurrent AccruedPayrollAndRelatedTaxesNoncurrent	77000	USD
CY2021Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	616000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	581000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1840000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1067000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3303000	USD
CY2021Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	608000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	2951000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	3010000	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	142000	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	142000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	159185000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	158589000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93568000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91325000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	65759000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	67406000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2564000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2384000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1535000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1138000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	1029000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	1246000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	702000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	312000	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	761000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	1960000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2274000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-714000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	31000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	31000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2243000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-713000	USD
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	-0	USD
CY2020Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3000	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2243000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-716000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	141915000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68898000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2243000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-713000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	59000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	34000	USD
CY2021Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	10000	USD
CY2020Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	10000	USD
CY2021Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	8000	USD
CY2020Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	8000	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	596000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	85000	USD
CY2021Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-111000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-286000	USD
CY2021Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	796000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	USD
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	40000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	106000	USD
CY2021Q3	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	22000	USD
CY2020Q3	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	56000	USD
CY2021Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2000	USD
CY2020Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	6000	USD
CY2021Q3	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-62000	USD
CY2020Q3	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-189000	USD
CY2021Q3	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-6000	USD
CY2020Q3	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	18000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2084000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-338000	USD
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	54000	USD
CY2020Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-54000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-113000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2138000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-451000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64010000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2573000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	61872000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2122000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61690000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1940000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61872000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2122000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5723000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	85000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-713000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	5095000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	67406000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	596000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2243000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	65759000	USD
CY2021Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9972000
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11672000
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	757000	USD
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	645000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	268000	USD
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	286000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	49000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	1060000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	980000	USD
CY2021Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	792000	USD
CY2021Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	76000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9259000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9206000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7306000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7248000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1953000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1958000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.58
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.46
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	2951600
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	40000
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99	pure
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.83	pure
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	596000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	85000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1572000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7326000
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y29D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	343000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7326000
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y29D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	343000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4205000
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y25D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	289000	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2951600
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	40000
CY2021Q3	isr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	1712000	USD
CY2020Q3	isr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	18000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	7500
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	132500
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2500
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	77000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	73000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	219000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	292000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	264000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	775000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	715000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	459000	USD

Files In Submission

Name	View Source	Status
0001437749-21-026208-index-headers.html	Edgar Link	pending
0001437749-21-026208-index.html	Edgar Link	pending
0001437749-21-026208.txt	Edgar Link	pending
0001437749-21-026208-xbrl.zip	Edgar Link	pending
ex_295134.htm	Edgar Link	pending
ex_295135.htm	Edgar Link	pending
ex_295136.htm	Edgar Link	pending
ex_295137.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
isr-20210930.xsd	Edgar Link	pending
isr-20210930_cal.xml	Edgar Link	unprocessable
isr-20210930_def.xml	Edgar Link	unprocessable
isr-20210930_lab.xml	Edgar Link	unprocessable
isr-20210930_pre.xml	Edgar Link	unprocessable
isr20210930_10q.htm	Edgar Link	pending
isr20210930_10q_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics Inc Stock $catx

2021 Q4 Form 10-Q Financial Statement

#000143774921026208 Filed on November 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics Inc Stock $catx

2021 Q4 Form 10-Q Financial Statement

#000143774921026208 Filed on November 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics Inc Stock $catx